RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle recurrent head and neck cancer
Disease control Recruiting nowThis study tests a combination of two investigational drugs, SHR-A2102 and adebrelimab, with or without other anti-cancer therapies, in people whose head and neck squamous cell carcinoma has returned or spread. The goal is to find safe and effective doses and see if the combinati…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Promising drug cocktail targets Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis phase II trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls 39 adults whose tumors have specific markers (Trop2 and CPS). The goal is to se…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis phase 2 trial tests two drugs, Iparomlimab and Tuvonralimab, in 30 adults with recurrent or metastatic head and neck cancer that has not responded to at least two prior treatments. Participants receive the drugs by IV every 21 days. The main goal is to see if the combination…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for head and neck cancer: drug combo shows promise after standard treatment fails
Disease control Recruiting nowThis study tests whether adding a chemotherapy drug (paclitaxel) to a targeted therapy (cetuximab) works better than cetuximab alone for people with advanced head and neck cancer that has worsened after initial treatment. About 65 adults with recurrent or metastatic squamous cell…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for head and neck cancer: smart drug targets tumors, boosts immune system
Disease control Recruiting nowThis phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples an…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Gut health boost may tame immunotherapy side effects in head and neck cancer
Disease control Recruiting nowThis study tests whether a postbiotic supplement (Postbiotix-HLA™) can reduce immune-related side effects in 45 people with recurrent or metastatic head and neck cancer who are receiving the immunotherapy drug pembrolizumab. Participants will take either the supplement or a place…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Scientists hunt for biomarkers to personalize head and neck cancer treatment
Knowledge-focused Recruiting nowThis study is analyzing blood and tumor samples from 30 people with advanced head and neck cancer who are receiving standard immunotherapy plus chemotherapy. The goal is to find biological markers that can predict who will respond well to treatment. By understanding changes in th…
Matched conditions: RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC